arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Protara Therapeutics, Inc.

TARA
$3.54 ▼ -0.15 (-4.19%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
55 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Weak
Bearish
auto_awesome

Analytical Summary

Protara Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $216.0M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC -11.4% ↘
FCF / Share $-0.25 ↗
Trailing P/E —
Price / Book 1.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-17.78M
↓ -49.3% —
FCF / Share Free cash flow per share
$-0.25
↑ +32.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns →
23
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 55 quarters